Neonatal piroplasmosis, an underestimated problem?





L.M. Hermans¹, A. Leblond², A. Josson¹, J. Gasco¹, C. Bonsergent³, L. Malandrin³









Clinéquine, VetAgro Sup, University of Lyon, Marcy l'Etoile 69280, France.
UMR EPIA, INRAE, VetAgro Sup, University of Lyon, Marcy l'Etoile 69280, France
Oniris, INRAE, UMR BIOEPAR, Nantes 44307, France

INTRODUCTION

- Piroplasmosis = tick-borne disease
- Etiology: Theileria equi and Babesia caballi



Lifecycle (Wise *et al.*, 2014) and morphology of *T. equi* et *B. caballi* on blood smear Yellow star: *B.* caballi, red star: *T. equi* (©Eve Ramery – Vetagro Sup)



Transmission routes of *T. equi* and *B. caballi* (modified from Onyiche *et al.*, 2019)

Clinical piroplasmosis in equine neonates is rare. Vertical transmission has been described with different clinical presentations

OBJECTIVES

• Estimate the frequency of vertical transmission of piroplasmosis etiological agents from infected asymptomatic broodmares to their foals

Observe the symptoms in positive newborns

MATERIALS

- Inclusions mares: spending > than 6 months/year on pasture, in last trimester of gestation
- Inclusions foals: < than 72 hours of age, born in a box/paddock

METHODS

- Blood smear evaluation
- Nested PCR
 - Foals from carrier mares → triplicate
- IFAT in PCR positive foals

RESULTS

71 mares and their foals, without clinical signs of piroplasmosis

Nested PCR	T. equi	B. caballi
Mares	25/71 (35,2%)	2/71 (2,8%)
Foals	2/25 (8%)	0/2 (0%)

Blood smear	T. equi	B. caballi
Mares	5/25 (20%)	0/2 (0%)
Foals	2/2 (100%)	0 (0%)

Positive serology result in both PCR positive foals: 1/1280

CONCLUSION AND CLINICAL RELEVANCE

- Confirmation of *T. equi* vertical transmission
 - Low transmission rate (8%)
 - No clinical signs of neonatal piroplasmosis
- Vertical transmission may be of importance for breeders
- No confirmation of vertical transmission B. caballi
 - → warrants more research

- No conflicts of interest to declare.
- The Animal Research Ethics Committee approved the study protocol (N°2211). Consent was given by owners or their representatives for the inclusion of their horse in the clinical trial.
- Funding: Programme National de Recherche Clinique Vétérinaire (PNR-CV), Écoles Nationales Vétérinaires de France (ENVF)
- Contacts: Lisa-Marie Hermans, Clinéquine, VetAgro Sup, University of Lyon, Marcy l'Etoile 69280, France, lisa-marie.hermans@vetagro-sup.fr